home LATEST ONCOPRESCRIBE UPDATES ADCETRIS® Improves Overall Survival in Stage III or IV Hodgkin’s LymphomaLate Breaking Abstract – ASCO 2022: Improved Distant Metastasis-Free Survival with Adjuvant KEYTRUDA® in High Risk Stage II MelanomaLate Breaking Abstract – ASCO 2022: RUBRACA® Monotherapy as Maintenance Treatment in Newly Diagnosed Ovarian CancerLate Breaking Abstract – ASCO 2022: Nimotuzumab Significantly Improves Overall Survival in K-Ras Wild-Type Advanced Pancreatic CancerLate Breaking Abstract – ASCO 2022: FOLFOXIRI Plus Bevacizumab in Unresectable Colorectal Cancer with Liver MetastasesLate Breaking Abstract – ASCO 2022: RVd Plus Autologous Stem Cell Transplantation and REVLIMID® Maintenance Improves PFS in Multiple MyelomaLate Breaking Abstract – ASCO 2022: ENHERTU® for HER2-Low Advanced Breast CancerScreening for Pancreatic Cancer Results in Early Detection and Improved Overall Survival SHOW MORE FDAApprovals Meeting Updates Hem/OncUpdates Symptom Management NEW REGIMENS ADDEDResearch RegimensTIBSOVO® - for Acute Myeloid Leukemia KEYTRUDA® - for Malignant Melanoma TECENTRIQ® and ABRAXANE® - for Breast CancerKEYTRUDA® plus INLYTA® - for Renal CancerPARAPLATIN® and VEPESID® with TECENTRIQ® - for Small Cell Lung Cancer Curbside ConsultationBiomarker Testing in NSCLC-Special IssueImmuno-OncologyPrecision OncologyCOVID-19 Associated Coagulopathy: Diagnosis and ManagementTTP, HUS and aHUS: Different diseases – Different treatmentsHER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateDual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal TumorsFDA Approves ENDARI®, A New Treatment for Sickle Cell DiseaseSHOW MORE